立体定向体部放疗治疗可手术早期肺癌:NRG Oncology RTOG 0618 试验结果
NRG Oncology RTOG 0618 是一项单臂 2 期研究,评估门诊 SBRT 对可手术早期非小细胞肺癌的疗效与安全性。33 例入组、26 例可评估,SBRT 总剂量 54 Gy 分 3 次。4 年原发肿瘤控制率和局部控制率均为 96%,治疗相关 3 级不良事件仅 2 例(8%)。
要点
- 可手术早期肺癌 SBRT 后 4 年原发肿瘤控制率 96%。
- 4 年无病生存率 57%,总生存率 56%,中位总生存 55.2 个月。
- 治疗相关 3 级不良事件 2 例(8%),无 4/5 级事件。
核心结论
- SBRT 在可手术早期肺癌中显示高原发肿瘤控制率、低治疗相关并发症和较少需手术挽救。
研究设计与样本
- 入组可手术、活检证实外周 T1-T2 N0 M0 非小细胞肺癌,肿瘤≤5 cm,FEV1 和弥散功能>35% 预计值,PaO2>60 mm Hg,PaCO2<50 mm Hg,无严重内科问题。
- SBRT 处方剂量 54 Gy,分 3 次每次 18 Gy,1.5-2.0 周内完成。
主要发现
- 33 例入组,26 例可评估(23 例 T1,3 例 T2;15 例[58%]男性;中位年龄 72.5 岁[范围 54-88 岁])。
- 仅 1 例原发肿瘤复发,无受累肺叶失败,估计 4 年原发肿瘤控制率和局部控制率均为 96%(95% CI,83%-100%)。
- 该例局部复发患者按方案在 SBRT 后 1.2 年接受挽救性肺叶切除,并发 4 级心律失常。
- 4 年无病生存率和总生存率分别为 57%(95% CI,36%-74%)和 56%(95% CI,35%-73%),中位总生存 55.2 个月(95% CI,37.7 个月至未达到)。
- 方案规定治疗相关 3 级、4 级和 5 级不良事件分别报告 2 例(8%;95% CI,0.1%-25%)、0 例和 0 例。
关键数值与推荐
- 原发肿瘤控制率为主要终点,生存、不良事件及手术挽救的发生与结局为次要终点。
临床怎么用
- 对可手术早期非小细胞肺癌患者,SBRT 可作为非侵入性门诊治疗选择,需结合患者具体情况和多学科评估。
局限性
- 单臂 2 期研究,样本量小(26 例可评估),非随机对照,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Stereotactic body radiation therapy (SBRT) has become a standard treatment for patients with medically inoperable early-stage lung cancer. However, its effectiveness in patients medically suitable for surgery is unclear. OBJECTIVE: To evaluate whether noninvasive SBRT delivered on an outpatient basis can safely eradicate lung cancer and cure selected patients with operable lung cancer, obviating the need for surgical resection. DESIGN, SETTING, AND PARTICIPANTS: Single-arm phase 2 NRG Oncology Radiation Therapy Oncology Group 0618 study enrolled patients from December 2007 to May 2010 with median follow-up of 48.1 months (range, 15.4-73.7 months). The setting was a multicenter North American academic and community practice cancer center consortium. Patients had operable biopsy-proven peripheral T1 to T2, N0, M0 non-small cell tumors no more than 5 cm in diameter, forced expiratory volume in 1 second (FEV1) and diffusing capacity greater than 35% predicted, arterial oxygen tension greater than 60 mm Hg, arterial carbon dioxide tension less than 50 mm Hg, and no severe medical problems. The data analysis was performed in October 2014. INTERVENTIONS: The SBRT prescription dose was 54 Gy delivered in 3 18-Gy fractions over 1.5 to 2.0 weeks. MAIN OUTCOMES AND MEASURES: Primary end point was primary tumor control, with survival, adverse events, and the incidence and outcome of surgical salvage as secondary end points. RESULTS: Of 33 patients accrued, 26 were evaluable (23 T1 and 3 T2 tumors; 15 [58%] male; median age, 72.5 [range, 54-88] years). Median FEV1 and diffusing capacity of the lung for carbon monoxide at enrollment were 72.5% (range, 38%-136%) and 68% (range, 22%-96%) of predicted, respectively. Only 1 patient had a primary tumor recurrence. Involved lobe failure, the other component defining local failure, did not occur in any patient, so the estimated 4-year primary tumor control and local control rate were both 96% (95% CI, 83%-100%). As per protocol guidelines, the single patient with local recurrence underwent salvage lobectomy 1.2 years after SBRT, complicated by a grade 4 cardiac arrhythmia. The 4-year estimates of disease-free and overall survival were 57% (95% CI, 36%-74%) and 56% (95% CI, 35%-73%), respectively. Median overall survival was 55.2 months (95% CI, 37.7 months to not reached). Protocol-specified treatment-related grade 3, 4, and 5 adverse events were reported in 2 (8%; 95% CI, 0.1%-25%), 0, and 0 patients, respectively. CONCLUSIONS AND RELEVANCE: As given, SBRT appears to be associated with a high rate of primary tumor control, low treatment-related morbidity, and infrequent need for surgical salvage in patients with operable early-stage lung cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00551369.
引用
- Timmerman RD, Paulus R, Pass HI, et al. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol. 2018. PMID: 29852037. doi:10.1001/jamaoncol.2018.1251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。